- Home
- SEED vs ASBP Comparison
SEED vs ASBP Comparison
Compare SEED & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEED | ASBP |
|---|---|---|
| Founded | 1997 | 2021 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 12.4M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SEED | ASBP |
|---|---|---|
| Price | $1.06 | $9.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.1K | ★ 26.2K |
| Earning Date | 01-30-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.05 |
| 52 Week High | $2.49 | $9.50 |
Technical Indicators
Market Signals| Indicator | SEED | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 61.99 |
| Support Level | $0.97 | $4.63 |
| Resistance Level | $1.05 | N/A |
| Average True Range (ATR) | 0.03 | 0.58 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 54.17 | 70.00 |
Price Performance
Historical ComparisonAbout SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.